Trial Profile

A Phase I/II, first-in-human, single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-001 in participants With Glanzmann thrombasthenia

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2025 Interim results of phase II presented in the Hemab Media Release.
24 Jun 2025 According to a Hemab media release, interim data from phase II presented at the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress.
10 Jun 2025 According to a Hemab media release, company announced that data from this study will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress in Washington, DC, on June 21-25, 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com